title: The Effect of Cilostazol on Endothelial Function as Assessed by Flow-Mediated Dilation in Patients with Coronary Artery Disease.
abstract: OBJECTIVE
  The vascular endothelium plays a key role in the pathophysiology of atherosclerosis. Flow-mediated dilation (FMD) is a novel way of assessing endothelial function. Cilostazol is a unique antiplatelet drug that also has the potential to improve endothelial function. The objective of this present study was to investigate the effects of cilosatzol on endothelial function as assessed by FMD.
  
  
  METHODS
  Fifty-one patients with coronary artery disease (CAD) were assigned to one of two groups: the Cilostazol(+) group (with cilostazol) and Cilostazol(-) group (without cilostazol). In addition to conventional dual antiplatelet therapy with aspirin and clopidogrel/ticlopidine, the Cilostazol(+) group (n=27) was also given cilostazol (100 mg/day). The Cilostazol(-) group (n=24) did not receive cilostazol. FMD was assessed at enrollment and after 6-9 months.
  
  
  RESULTS
  The FMD of both the Cilostazol(+) and Cilostazol(-) groups remained similar at 5.2 (interquartile range: 3.8-8.5) to 5.4 (interquartile range: 4.2-6.7) (P=0.29) and 5.0 (interquartile range: 3.6-6.4) to 4.9 (interquartile range: 4.0-7.0) (P=0.38), respectively. However, the diameters of the baseline and maximal brachial arteries tended to increase in the Cilostazol(+) group (baseline: 4.2±0.7 to 4.4±0.7, P=0.18; maximal: 4.5±0.7 to 4.6±0.7 P=0.22), whereas that of the Cilostazol(-) group tended to decrease (baseline: 4.1±0.6 to 3.9±0.5, P=0.10; maximal: 4.3±0.7 to 4.1±0.5, P=0.05). The rates of change in the baseline diameter (Cilostazol(+): 3.7±9.8% vs. Cilostazol(-): -3.8±12.2%, P=0.03) and maximal diameter (Cilostazol(+): +3.1±8.9% vs. Cilostazol(-): -4.4±12.0%, P=0.02) were significantly different.
  
  
  CONCLUSIONS
  Although cilostazol didn't affect the FMD, there was a significant difference in the rates of change in baseline and maximal brachial artery diameter. This may have a beneficial effect in patients with cardiovascular disease.
authors.affiliation: Department of Cardiology, Showa University Fujigaoka Hospital.
authors.forename: Hiroyoshi
authors.initials: H
authors.lastname: Mori
authors.forename: Atsuo
authors.initials: A
authors.lastname: Maeda
authors.forename: Kohei
authors.initials: K
authors.lastname: Wakabayashi
authors.forename: Tokutada
authors.initials: T
authors.lastname: Sato
authors.forename: Masahiro
authors.initials: M
authors.lastname: Sasai
authors.forename: Kazuma
authors.initials: K
authors.lastname: Tashiro
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Iso
authors.forename: Mio
authors.initials: M
authors.lastname: Ebato
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Suzuki
mesh_terms: D000368:Aged; D001993:Bronchodilator Agents / Q000494:pharmacology*; D000077407:Cilostazol; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000503:physiopathology; D004106:Dilatation / Q000379:methods*; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism; D005260:Female; D006801:Humans; D008297:Male; D011446:Prospective Studies; D013777:Tetrazoles / Q000494:pharmacology*
chemical_list: D001993:Bronchodilator Agents; D013777:Tetrazoles; D000077407:Cilostazol